- Home
- ABSI vs PRQR Comparison
ABSI vs PRQR Comparison
Compare ABSI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.4M | 250.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABSI | PRQR |
|---|---|---|
| Price | $4.05 | $2.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $7.98 | ★ $8.14 |
| AVG Volume (30 Days) | ★ 3.4M | 586.4K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,815,000.00 | ★ $18,859,556.00 |
| Revenue This Year | $10.72 | N/A |
| Revenue Next Year | $437.79 | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $1.07 |
| 52 Week High | $6.33 | $3.10 |
Technical Indicators
Market Signals| Indicator | ABSI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 53.03 |
| Support Level | $3.40 | $1.92 |
| Resistance Level | $3.79 | $2.31 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 91.39 | 72.72 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.